ITC Research Talent Hub: related project: Incu-Bio Programme: BP InnoMed Limited - Inhibitor For EBV-associated Malignancies

BP InnoMed Limited is dedicated to developing and commercializing theranostics inhibitors to eradicate Epstein-Barr Virus (EBV)-associated cancers. EBV infects over 90% of the population, with 200,000 new cases of related cancers diagnosed annually. Nasopharyngeal carcinoma (NPC), prevalent in southern China, accounts for over 4,000 cases in Guangzhou each year, with more than 80% at stages 3 and 4. Nearly all NPC tumors in endemic regions are EBV-positive. We have successfully established several EBV-targeting agents and aim to translate our basic science knowledge into therapeutic options for NPC patients. Our primary goal is to develop anti-EBV agents for clinical trials. In the future, we plan to create a range of theranostic probes, molecular sensors, and pro-drugs for cancer diagnosis and therapy. Our mission is to provide low-cost, effective medical products to enhance cancer therapy and improve diagnostic efficiency for clinicians worldwide.